Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H26N2.C4H4O4 |
Molecular Weight | 410.506 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CC(CN(C)C)CN1C2=C(CCC3=C1C=CC=C3)C=CC=C2
InChI
InChIKey=YDGHCKHAXOUQOS-BTJKTKAUSA-N
InChI=1S/C20H26N2.C4H4O4/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22;5-3(6)1-2-4(7)8/h4-11,16H,12-15H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula | C20H26N2 |
Molecular Weight | 294.4338 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Trimipramine is a tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. It was sold under brand name surmontil for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. Trimipramine has been reported to differ from other typical tricyclic antidepressant drugs in several aspects, for instance it does not inhibit neuronal transmitter uptake and does not cause down-regulation of beta-adrenoceptors. Moreover, it may possess antipsychotic activity in schizophrenic patients. In addition, was found that it did not antagonize the inhibitory effect of noradrenaline and 5-hydroxytryptamine on the release of transmitter, mediated by presynaptic auto receptors. In radioligand binding studies, trimipramine showed fairly high affinities for some dopamine (DA), noradrenaline and 5-hydroxytryptamine (5-HT) receptor subtypes (5-HT2 receptors = alpha 1A/B-adrenoceptors greater than or equal to D2 receptors), intermediate affinities for D1 receptors, alpha 2B-adrenoceptors and 5-HT1C receptors but only low affinities for alpha 2A-adrenoceptors, 5-HT1A, 5-HT1D and 5-HT3 receptors. It may thus be classified as an atypical neuroleptic drug.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1663593 |
|||
Target ID: CHEMBL2095200 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1663593 |
|||
Target ID: CHEMBL2096676 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1663593 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SURMONTIL Approved UseSURMONTIL is indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. Launch Date1979 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
92.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14520122/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMIPRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.13 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14520122/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMIPRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
31 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14520122/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIMIPRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
yes [IC50 31 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
yes [Km 258 uM] | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Polysomnographic effects of adjuvant ginkgo biloba therapy in patients with major depression medicated with trimipramine. | 2001 Mar |
|
Connection between lithium and muscular incoordination. | 2002 Feb |
|
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. | 2002 Oct |
|
Effects of REM sleep awakenings and related wakening paradigms on the ultradian sleep cycle and the symptoms in depression. | 2002 Sep-Oct |
|
Optimised procedures for the reversed-phase liquid chromatographic analysis of formulations containing tricyclic antidepressants. | 2003 Apr 24 |
|
Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. | 2003 Dec |
|
Trimipramine determination in pharmaceutical preparations with an automated multicommutated reversed-flow system. | 2003 Dec 4 |
|
Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. | 2005 Jan |
|
[Multiple fibromas in systemic mastocytosis]. | 2005 May |
|
Depression and sleep: pathophysiology and treatment. | 2006 |
|
A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. | 2006 Feb |
|
Trimipramine for refractory panic attacks. | 2006 Mar |
|
Receptor occupancy of mirtazapine determined by PET in healthy volunteers. | 2007 Nov |
|
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | 2008 Feb |
|
Frequency of different anti-depressants associated with suicides and drug deaths. | 2008 Mar |
|
The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. | 2009 |
|
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases. | 2009 Oct |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
Sample Use Guides
Outpatients and Office Patients: initially, 75 mg/day in divided doses, increased to 150 mg/day. Dosages over 200 mg/day are not recommended. Maintenance therapy is in the range of 50 to 150 mg/day. For convenient therapy and to facilitate patient compliance, the total dosage requirement may be given at bedtime.
Hospitalized Patient: initially, 100 mg/day in divided doses. This may be increased gradually in a few days to 200 mg/day, depending upon individual response and tolerance. If improvement does not occur in 2 to 3 weeks, the dose may be increased to the maximum recommended dose of 250 to 300 mg/day.
Adolescent and Geriatric Patients: initially, a dose of 50 mg/day is recommended, with gradual increments up to 100 mg/day, depending upon patient response and tolerance.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21484238
It was investigated whether trimipramine and three of its metabolites interact with targets of other antidepressants, namely, the human monoamine transporters for noradrenaline (hNAT), serotonin (hSERT), and dopamine (hDAT), and with the human organic cation transporters (hOCT1, hOCT2, and hOCT3) which are expressed in the brain and are known to be involved in the uptake of monoamines. HEK293 cells heterologously expressing the abovementioned transporters were used to determine the inhibition of [(3)H]MPP(+) uptake by trimipramine and its main metabolites. At concentrations up to 30 μM, all transporters, except hOCT3, were inhibited by all examined substances. With IC(50) values between 2 and 10 μM, trimipramine inhibited hSERT, hNAT, hOCT1, and hOCT2, whereas clearly higher concentrations were needed for half-maximal inhibition of hDAT. Desmethyl-trimipramine showed about the same potencies as trimipramine, whereas 2-hydroxy-trimipramine was less potent at hNAT, hSERT, and hOCT1. Trimipramine-N-oxide preferentially inhibited hSERT.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:33:57 GMT 2025
by
admin
on
Mon Mar 31 19:33:57 GMT 2025
|
Record UNII |
269K6498LD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C94727
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID2045315
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
208-318-3
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
1692709
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
20230-75-5
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
269K6498LD
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
m11164
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
35030
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
SUB04977MIG
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
71532
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
DBSALT000969
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
CHEMBL644
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
758386
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
1217260-65-5
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
100000084667
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
521-78-8
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
C47773
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
269K6498LD
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY | |||
|
5282318
Created by
admin on Mon Mar 31 19:33:57 GMT 2025 , Edited by admin on Mon Mar 31 19:33:57 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |